We are live on
!
Find out more
PA
PharVision Advisers Portfolio holdings
AUM
$9.86M
1-Year Est. Return
9.93%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+9.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
+$19.8M
(+11%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
11.78%
Top 10 Holdings %
Top 10 Hldgs %
3.45%
Holding
1,063
New
409
Increased
141
Reduced
117
Closed
396
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek US
DK
|
+$871K |
| 2 |
Broadcom
AVGO
|
+$691K |
| 3 |
Agilent Technologies
A
|
+$650K |
| 4 |
Telos
TLS
|
+$640K |
| 5 |
Pagaya Technologies
PGY
|
+$627K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Technologies
ARRY
|
+$730K |
| 2 |
Vertiv
VRT
|
+$639K |
| 3 |
Zevra Therapeutics
ZVRA
|
+$635K |
| 4 |
BOW
Bowhead Specialty Holdings
BOW
|
+$608K |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$581K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Industrials | 15.13% |
| 3 | Financials | 12.4% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Healthcare | 11.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Liberty Latin America Class C
LILAK
$1.66B
| $221K | 0.11% |
+32,568
| New | +$244K |
|
477
Commerce Bancshares
CBSH
$8.69B
| $221K | 0.11% |
+4,214
| New | +$220K |
|
478
Bank of N.T. Butterfield & Son
NTB
$2.41B
| $220K | 0.11% |
+4,424
| New | +$204K |
|
479
Blue Owl Capital
OWL
$6.51B
| $220K | 0.11% |
+14,748
| New | +$231K |
|
480
Teladoc Health
TDOC
$1.68B
| $220K | 0.11% |
+31,473
| New | +$246K |
|
|
EXE
481
Expand Energy Corp
EXE
$22.2B
| $220K | 0.11% |
+1,993
| New | +$221K |
|
482
Roblox
RBLX
$36.1B
| $220K | 0.11% |
2,714
+1,139
| +72% | +$121K |
|
|
PSIX
483
Power Solutions International
PSIX
$597M
| $220K | 0.11% |
+3,843
| New | +$274K |
|
484
Oil-Dri
ODC
$1.44B
| $219K | 0.11% |
+4,484
| New | +$248K |
|
485
Canadian National Railway
CNI
$78.5B
| $219K | 0.11% |
+2,219
| New | +$213K |
|
|
GRRR
486
Gorilla Technology Group
GRRR
$306M
| $218K | 0.11% |
+19,966
| New | +$297K |
|
|
CTO
487
CTO Realty Growth
CTO
$760M
| $218K | 0.11% |
+11,818
| New | +$202K |
|
488
Merit Medical Systems
MMSI
$4.75B
| $217K | 0.11% |
2,467
-722
| -23% | -$61.4K |
|
489
Gold Fields
GFI
$28.9B
| $217K | 0.11% |
+4,980
| New | +$208K |
|
490
Bristow Group
VTOL
$1.33B
| $217K | 0.11% |
+5,933
| New | +$223K |
|
491
CBRE Group
CBRE
$44.2B
| $217K | 0.11% |
1,351
-49
| -4% | -$7.7K |
|
492
AXIS Capital
AXS
$7.73B
| $217K | 0.11% |
+2,028
| New | +$201K |
|
493
HCA Healthcare
HCA
$91.2B
| $217K | 0.11% |
465
-14
| -3% | -$6.5K |
|
494
Arhaus
ARHS
$1.1B
| $217K | 0.11% |
19,359
-11,200
| -37% | -$116K |
|
495
RCI Hospitality Holdings
RICK
$202M
| $217K | 0.11% |
+9,101
| New | +$233K |
|
496
Avnet
AVT
$6.97B
| $217K | 0.11% |
+4,503
| New | +$221K |
|
497
Peapack-Gladstone Financial
PGC
$819M
| $216K | 0.11% |
+7,770
| New | +$212K |
|
|
ARI
498
Apollo Commercial Real Estate
ARI
$862M
| $216K | 0.11% |
+22,350
| New | +$224K |
|
|
NGD
499
DELISTED
New Gold Inc
NGD
| $216K | 0.11% |
24,789
+7,406
| +43% | +$55.8K |
|
500
Innospec
IOSP
$2.11B
| $216K | 0.11% |
+2,817
| New | +$213K |
|
Similar funds
BS
RG
MP
CCM
DFA
CCP
FRT
VH
PharVision Advisers's Q4 2025 Portfolio in Review
As of Q4 2025, PharVision Advisers held 1,063 positions worth $198M, up 11% from $178M the previous quarter. Its ten largest holdings account for 3.5% of the portfolio.
PharVision Advisers deployed $23.3M of net new capital in Q4 2025, opening 409 new positions and adding to 141 existing holdings. Its largest new stake was Delek US: 24,407 shares worth $724K.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Wayfair, an estimated $510K trimmed.
- PharVision Advisers's largest Q4 2025 buy was Delek US: 24,407 shares worth $724K.
- PharVision Advisers added most to NIO in Q4 2025, an estimated $557K increase.
- PharVision Advisers's biggest Q4 2025 reduction was Wayfair, cutting an estimated $510K.
- PharVision Advisers fully exited Array Technologies in Q4 2025, selling an estimated $730K.
- PharVision Advisers's ten largest holdings make up 3.5% of its $198M portfolio in Q4 2025.
- PharVision Advisers opened 409 new positions and closed 396 in Q4 2025.
- PharVision Advisers's portfolio value rose 11% quarter-over-quarter to $198M.
Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.